Duke University - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
76
About the Report
About the Report
Summary
Duke University (Duke) is an educational consulting institution that offers in-business and graduation services. The institution provides education and graduation services through its schools and institutes. Its educational fields include in divinity, business, the environment, engineering, medicine, law, nursing, public policy and others. Duke's services include technology administration, human resource services, transportation, dining, safety and security; finance, stores, campus services, academic services and other facilities. The institute's transportation services include buses, parking and permits; van operations, alternative transportation, disability management and map services. It also conducts activities including basketball, lacrosse and soccer, and women's golf and tennis, and research on marine biotechnology and biomedicine. The institution provides research support services. Duke is headquartered in Durham, North Carolina, the US.
Duke University-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Duke University, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Duke University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Duke University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Duke University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Duke University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Duke University, Medical Devices Deals, 2012 to YTD 2018 10
Duke University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Duke University, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Grid Therapeutics Raises Funds through Series A Financing 13
Partnerships 14
Enzyvant Enters into Collaboration Agreement with Visikol and Duke University 14
Axsome Therapeutics Enters into Research Agreement with Duke University 15
Sarepta Therapeutics Enters into Research Agreement with Duke University 16
DelMar Pharma Enters into Partnership with Duke University 17
Tempus Labs Enters into Agreement with Duke University School of Medicine 18
Immunomic Therapeutics Enters into Research Agreement with Duke University 19
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 20
CellepathicRx Forms Joint Venture With Duke University 22
VistaGen Therapeutics Enters Into Research Agreement With Duke University 23
Bristol-Myers Squibb Enters Into Co-Development Agreement With Duke Translational Medicine Institute 24
Licensing Agreements 25
Radius Health Enters into Licensing Agreement with Duke University 25
Actus Therapeutics Enters into Licensing Agreement with Duke University 26
Grid Therapeutics Enters into Licensing Agreement with Duke University 27
Enzyvant Sciences Enters into Licensing Agreement with Duke University 28
Sermonix Pharma Enters into Licensing Agreement with Duke University 29
Duke University Enters into Licensing Agreement with PhaseBio Pharma 30
Cocrystal Pharma Enters into Licensing Agreement with Duke University and Emory University 31
Medifocus Enters into Licensing Agreement with Duke University 33
Annias Immunotherapeutics Enters into Licensing Agreement with Duke Cancer Institute 34
Editas Medicine Enters into Licensing Agreement with Duke University 35
Trovagene Enters Into Licensing Agreement With Duke University And Duke University Health Systems For NPM1 Marker 36
Duke University-Key Competitors 37
Duke University-Key Employees 38
Duke University-Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Joint Venture 41
Recent Developments 42
Government and Public Interest 42
Jul 24, 2018: NIH expands program that conducts large-scale clinical trials in real-world settings 42
Jul 18, 2018: Mystery Solved: How lymphoblastic leukemia enters central nervous system 43
Jun 19, 2018: ERAS Cardiac Surgery Officially Joins ERAS Society at World Congress in Stockholm 44
May 23, 2018: Foundation for Anesthesia Education and Research Awards USD 1.4 million in Grants 45
May 14, 2018: Duke Receives USD 60 Million NIH Grant to Speed Medical Research into Practice 48
May 01, 2018: Strategy prevents blindness in mice with retinal degeneration 50
Mar 06, 2018: Overlooked Cell Key Player in Preventing Age-Related Vision Loss 51
Jan 23, 2018: Damon Runyon Cancer Research Foundation awards USD 3M to eleven innovative early career scientists 52
Jan 08, 2018: Engineers Grow Functioning Human Muscle from Skin Cells 55
Jan 02, 2018: A Safer Route to Ultrasonic Therapy 57
Oct 27, 2017: New molecule shows promise in HIV vaccine design 58
Oct 06, 2017: FDA awards 15 grants for clinical trials to stimulate product development for rare diseases 59
Sep 27, 2017: New immunotherapy trial shows promising results for brain tumours 61
Sep 20, 2017: Space research institute awards 10 research grants 62
Sep 07, 2017: NIH awards nearly USD 100 million for Autism Centers of Excellence program 64
Jul 28, 2017: Scientists Use New Data Mining Strategy to Spot Those at High Alzheimer's Risk 66
Mar 13, 2017: University Of Utah Engineers Use CRISPR Technology To Prevent Tissue Damage And Resulting Chronic Pain 67
Jan 12, 2017: Developing New Strategies for Cancer Drug Delivery, in Denmark and at Duke 68
Product News 70
May 21, 2018: Biomaterial developed at UCLA helps regrow brain tissue after stroke in mice 70
May 07, 2018: Artificial intelligence detects patterns of gut microbes that indicate cholera risk 71
Other Significant Developments 73
Jul 26, 2018: Desperately ill patients will get better access to experimental treatments through new effort 73
May 07, 2018: AI Detects Patterns of Gut Microbes for Cholera Risk 75
Appendix 76
Methodology 76
About GlobalData 76
Contact Us 76
Disclaimer 76
List of Figure
List of Figures
Duke University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Duke University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Duke University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Duke University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Duke University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Duke University, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Duke University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Duke University, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Duke University, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Duke University, Pharmaceuticals & Healthcare, Key Facts 2
Duke University, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Duke University, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Duke University, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Duke University, Deals By Therapy Area, 2012 to YTD 2018 9
Duke University, Medical Devices Deals, 2012 to YTD 2018 10
Duke University, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Grid Therapeutics Raises Funds through Series A Financing 13
Enzyvant Enters into Collaboration Agreement with Visikol and Duke University 14
Axsome Therapeutics Enters into Research Agreement with Duke University 15
Sarepta Therapeutics Enters into Research Agreement with Duke University 16
DelMar Pharma Enters into Partnership with Duke University 17
Tempus Labs Enters into Agreement with Duke University School of Medicine 18
Immunomic Therapeutics Enters into Research Agreement with Duke University 19
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 20
CellepathicRx Forms Joint Venture With Duke University 22
VistaGen Therapeutics Enters Into Research Agreement With Duke University 23
Bristol-Myers Squibb Enters Into Co-Development Agreement With Duke Translational Medicine Institute 24
Radius Health Enters into Licensing Agreement with Duke University 25
Actus Therapeutics Enters into Licensing Agreement with Duke University 26
Grid Therapeutics Enters into Licensing Agreement with Duke University 27
Enzyvant Sciences Enters into Licensing Agreement with Duke University 28
Sermonix Pharma Enters into Licensing Agreement with Duke University 29
Duke University Enters into Licensing Agreement with PhaseBio Pharma 30
Cocrystal Pharma Enters into Licensing Agreement with Duke University and Emory University 31
Medifocus Enters into Licensing Agreement with Duke University 33
Annias Immunotherapeutics Enters into Licensing Agreement with Duke Cancer Institute 34
Editas Medicine Enters into Licensing Agreement with Duke University 35
Trovagene Enters Into Licensing Agreement With Duke University And Duke University Health Systems For NPM1 Marker 36
Duke University, Key Competitors 37
Duke University, Key Employees 38
Duke University, Other Locations 39
Duke University, Subsidiaries 39
Duke University, Joint Venture 41
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.